This study is aimed to assess the correct real-world use of an autoinjector for the repeat
self-administration of mepolizumab SC, so to improve subject / physician convenience and to
enable repeat dose self injection themselves or via caregivers. This Phase III study will be
an open-label, single-arm, repeat-dose, multi-centre study of mepolizumab liquid drug product
in autoinjector (100 milligrams [mg]) administered subcutaneously (SC) every 4 weeks (3
doses) in subjects with severe eosinophilic asthma. Subjects will receive 100 mg mepolizumab
SC as a single injection that is self-administered in the thigh, abdomen or administered in
the upper arm (caregiver only). Each subject will participate in the study for up to 18 weeks
including pre-screening visit, a screening visit and a 12-week treatment period which
concludes with end of study assessments (Visit 5) 4 weeks after the last dose of mepolizumab.
Approximately 158 subjects will be enrolled in the study.